An Overlooked Impact of GLP-1 Receptor Agonists on Enteric Coated Medications

Eman Atef*

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used for diabetes and obesity, have seen exponential use in recent years, necessitating proper evaluation of their potential for drug-drug interactions (DDIs). Several studies have explored DDIs with commonly co-administered medications or narrow-therapeutic-index drugs using both clinical trial data and pharmacokinetic modelling approaches. These investigations have provided valuable insights but remain incomplete.

GLP-1 RAs alter multiple physiological functions that can affect the pharmacokinetics of co-administered oral drugs. Delayed gastric emptying remains the most extensively studied mechanism, with established effects on key parameters including Cmax, tmax, and AUC. However, other mechanisms such as altered intestinal motility, changes in splanchnic blood flow, and modified gut hormone secretion may also contribute.

This commentary focuses specifically on an underexplored DDI: the interaction between GLP-1 RAs and delayed-release (enteric-coated) formulations. By integrating pharmaceutical, biopharmaceutical, and pathopharmacological principles, we predict potential clinical outcomes when delayed-release drugs are co-administered with GLP-1 RAs, highlighting critical considerations for prescribers.

Keywords:

Published on: Jul 22, 2026 Pages: 13-17

Full Text PDF Full Text HTML DOI: 10.17352/ojpp.000030
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat